TCGA-JL-A3YX-01A-11R-A22U-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.530
- OXIDATIVE_PHOSPHORYLATION+0.400
- MYC_TARGETS_V1+0.340
- DNA_REPAIR+0.310
- ESTROGEN_RESPONSE_EARLY+0.310
- ESTROGEN_RESPONSE_LATE+0.310
- E2F_TARGETS+0.240
- FATTY_ACID_METABOLISM+0.230
- MYOGENESIS+0.230
- P53_PATHWAY+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.450
- IL6_JAK_STAT3_SIGNALING-0.390
- NOTCH_SIGNALING-0.380
- UV_RESPONSE_DN-0.380
- INFLAMMATORY_RESPONSE-0.360
- PROTEIN_SECRETION-0.360
- COMPLEMENT-0.350
- KRAS_SIGNALING_UP-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66O-01A-11R-A31O-07 | — | B | 0.854 |
| 2 | TCGA-F7-A61V-01A-11R-A28V-07 | — | — | 0.845 |
| 3 | TCGA-B6-A0IE-01A-11R-A034-07 | — | B | 0.836 |
| 4 | fa32f303-025b-40d2-a9b0-25bc7622c27e | — | — | 0.834 |
| 5 | TCGA-AO-A0J7-01A-11R-A034-07 | — | B | 0.831 |
| 6 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.825 |
| 7 | TCGA-AC-A62V-01A-11R-A31O-07 | — | B | 0.823 |
| 8 | TCGA-33-AASB-01A-11R-A405-07 | — | cohortA4 | 0.818 |
| 9 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.815 |
| 10 | 43c87798-5762-42c1-b7d8-47fc126fc2d3 | — | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |